---
phase: 05-workbench-visualization-enhancements
plan: "08"
subsystem: fda-product-labels domain
tags: [domain-schema, gap-closure, fda, labtest]
dependency_graph:
  requires: []
  provides: [fda-product-labels LABTEST entity type]
  affects: [domains/fda-product-labels/domain.yaml, domains/fda-product-labels/SKILL.md, domains/fda-product-labels/references/entity-types.md]
tech_stack:
  added: []
  patterns: [schema additive extension, prompt table row + numbered guideline]
key_files:
  modified:
    - domains/fda-product-labels/domain.yaml
    - domains/fda-product-labels/SKILL.md
    - domains/fda-product-labels/references/entity-types.md
decisions:
  - Use SCREAMING_SNAKE_CASE form LABTEST (not CamelCase LabTest) to match the 16 sibling entity types in domain.yaml
  - No new relation type added: HAS_WARNING and CAUSES_ADVERSE_REACTION already cover labeling sections where LabTests appear; MONITORED_BY deferred to a future dedicated plan
metrics:
  duration: ~10 minutes
  completed: "2026-04-25"
  tasks_completed: 1
  tasks_total: 1
  files_modified: 3
---

# Phase 05 Plan 08: Add LABTEST Entity Type to fda-product-labels Domain Summary

**One-liner:** Added LABTEST entity type to fda-product-labels domain schema, extraction prompt, and reference docs to satisfy REQUIREMENTS.md FDA-01.

## What Was Built

Gap closure for REQUIREMENTS.md FDA-01: the `fda-product-labels` domain previously defined 16 entity types but was missing `LABTEST` — a required type for capturing laboratory monitoring tests (LFTs, CBC, INR, lipid panels, etc.) referenced in drug label sections for hepatotoxic, immunosuppressive, and other drug classes.

Three files were updated additively with no deletions and no changes to existing entries.

### Exact YAML snippet inserted into `domains/fda-product-labels/domain.yaml`

Inserted after the `REGULATORY_IDENTIFIER` block, before `relation_types:`:

```yaml
  LABTEST:
    description: A laboratory monitoring test referenced in the label for tracking
      drug safety or efficacy (e.g. liver function tests for hepatotoxic drugs, CBC
      for immunosuppressants, lipid panels for statins, INR for anticoagulants)
```

Entity type count: 16 → 17. Relation types (16) and `community_label_anchors` unchanged.

### Exact table row inserted into `domains/fda-product-labels/SKILL.md`

New last row appended to the Entity Types table (before `## Relation Types`):

```
| LABTEST | A laboratory monitoring test referenced in the label for tracking drug safety or efficacy (e.g. liver function tests for hepatotoxic drugs, CBC for immunosuppressants, lipid panels for statins, INR for anticoagulants) |
```

### Exact extraction guideline 17 inserted into `domains/fda-product-labels/SKILL.md`

Appended after step 16 in the Extraction Guidelines section:

```
17. Extract LABTEST from sections that reference laboratory monitoring (warnings_and_cautions, adverse_reactions, clinical_pharmacology); create one entity per distinct test (e.g. ALT, AST, total bilirubin, complete blood count, serum creatinine, INR, lipid panel); prefer named tests over generic phrases like "blood work". Include the monitoring purpose as context when stated (e.g. "monitor LFTs every 4 weeks during therapy").
```

### Exact section inserted into `domains/fda-product-labels/references/entity-types.md`

Appended at end of file after blank line:

```markdown

## LABTEST
A laboratory monitoring test referenced in the label for tracking drug safety or efficacy (e.g. liver function tests for hepatotoxic drugs, CBC for immunosuppressants, lipid panels for statins, INR for anticoagulants)
```

## git diff --stat domains/fda-product-labels/

```
 domains/fda-product-labels/SKILL.md                   | 2 ++
 domains/fda-product-labels/domain.yaml                | 4 ++++
 domains/fda-product-labels/references/entity-types.md | 3 +++
 3 files changed, 9 insertions(+)
```

## Pytest result

```
96 passed, 2 skipped in 19.80s
```

## No new relation type

No new relation type was added in this gap closure. The existing `HAS_WARNING` and `CAUSES_ADVERSE_REACTION` relation types already connect `DRUG_PRODUCT` to the labeling sections where `LABTEST` entities appear (warnings_and_cautions, adverse_reactions). If a dedicated `MONITORED_BY` relation (DRUG_PRODUCT → LABTEST) is desired in v2, it should be its own dedicated plan.

## Decisions Made

1. **SCREAMING_SNAKE_CASE convention**: Used `LABTEST` (not `LabTest`) to match the naming convention of all 16 sibling entity types in domain.yaml. The verifier's `grep -i 'labtest'` matches `LABTEST`.

2. **No new relation type**: Deferred `MONITORED_BY` to a future plan — existing relations are sufficient for the FDA-01 requirement.

## Deviations from Plan

None — plan executed exactly as written. All three exact snippets from the `<interfaces>` block were inserted verbatim.

## Self-Check: PASSED

- `domains/fda-product-labels/domain.yaml` exists and contains LABTEST with 17 entity types total
- `domains/fda-product-labels/SKILL.md` contains LABTEST table row and guideline 17
- `domains/fda-product-labels/references/entity-types.md` contains `## LABTEST` section
- Commit `980601c` exists in worktree git log
- pytest: 96 passed, 2 skipped
